A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
{{output}}
Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via both Notch2 and No... ...
